Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cys1,D-Arg8]-vasopressin (dDAVP)

American Journal of Physiology - Endocrinology and Metabolism

Volumn 287, Issue 5 50-5, 2004, Pages

  Yamaguchi, Yoshitaka ^a   Yamada, Kenichi ^a,b   Suzuki, Toshikazu ^a   Wu, Yu Ping ^a,b   Kita, Kazuko ^a   Takahashi, Shunji ^a   Ichinose, Masaharu ^a   Suzuki, Nobuo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b SAKURA NATIONAL HOSPITAL   (Japan)

Author keywords

Arginine vasopressin; Plasminogen activator; Protease release; Urokinase type plasminogen activator

Indexed keywords

ARGIPRESSIN RECEPTOR; DESMOPRESSIN; OXYTOCIN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; UROKINASE; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN[1 ADAMANTANEACETYL 2 DEXTRO TYROSINE O ETHYL ESTER 4 VALINE 6 AMINOBUTYRYL 8,9 ARGININE]; VASOPRESSIN[1 BETA MERCAPTO BETA,BETA CYCLOPENTAMETHYLENEPROPIONYL 2 TYROSINE O METHYL ESTER 8 ARGININE];

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ARGININE VASOPRESSIN; CELLS, CULTURED; DEAMINO ARGININE VASOPRESSIN; HUMANS; LYMPHOCYTES; RECEPTOR CROSS-TALK; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 6044234748     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00027.2003     Document Type: Article

References (40)

1. Bickerstaff AA, Xia D, Pelletier RP, and Orosz CG. Mechanisms of graft acceptance: evidence that plasminogen activator controls donor-reactive delayed-type hypersensitivity responses in cardiac allograft acceptor mice. J Immunol 164: 5132-5139, 2000.
2. Bossmar T, Åkerlund M, Szamatowicz J, Laudanski T, Fantoni G, and Maggi M. Receptor-mediated uterine effects of vasopressin and oxytocin in nonpregnant women. Br J Obstet Gynaecol 102: 907-912, 1995.
3. Conrad KP, Gellai M, North WG, and Valtin H. Influence of oxytocin on renal hemodynamics and electrolyte and water excretion. Am J Physiol Renal Fluid Electrolyte Physiol 251: F290-F296, 1986.
4. Culpepper RM, Hebert SC, and Andreoli TE. The posterior pituitary and water metabolism. In: Textbook of Endocrinology, edited by Wilson JD and Foster DW. Philadelphia, PA: Saunders, 1985, p. 614-652.
5. Forsling ML and Brimble MJ. The role of oxytocin in salt and water balance. In: Oxytocin: Clinical and Laboratory Studies, edited by Amico JA and Robinson AG. Amsterdam: Elsevier, 1985, p. 167-175.
6. Hasunuma K, Yamada K, Tamura T, and Yoshida S. Cardiovascular and rennin responses to desmopressin in humans: role of prostacyclin and adrenergic systems. Am J Physiol Heart Circ Physiol 260: H1031-H1036, 1991.
7. Hunter WM and Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194: 495-496, 1962.
8. 2-receptor. FEBS Lett 315: 134-138, 1993.
9. Katusic ZS, Shepherd JT, and Vanhoutte PM. Vasopressin causes endothelium-dependent relaxation of the canine basilar artery. Circ Res 55: 575-579, 1984.
10. 2 receptor transduction pathways. Biochem J 330: 1023-1028, 1998.
11. Kobrinsky NL, Doyle JJ, Israels ED, Winter JSD, Cheang MS, Walker RD, and Bishop AJ. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus. Lancet 1: 1293-1294, 1985.
12. Lethagen S. Desmopressin (DDAVP) and haemostasis. Ann Hematol 69: 173-180, 1994.
13. Liard JF. Characterization of acute hemodynamic effects of antidiuretic agonists in conscious dogs. J Cardiovasc Pharmacol 11: 174-180, 1988.
14. Loscalzo J and Braunwald E. Tissue plasminogen activator. N Engl J Med 319: 925-931, 1988.
15. Lyness J, Robinson AG, Sheridan MN, and Gash DM. Antidiuretic effects of oxytocin in Brattleboro rat. Experientia 41: 1444-1446, 1985.
16. Mannucci PM, Canciani MT, Rota L, and Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 47: 283-293, 1981.
17. Mannucci PM and Rota L. Plasminogen activator response after DDAVP. A clinico-pharmacological study. Thromb Res 20: 69-76, 1980.
18. Michell RJ, Kirk CJ, and Billah MM. Hormonal stimulation of phosphatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 7: 861-865, 1979.
19. 2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes. Br J Pharmacol 129: 1700-1706, 2000.
20. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, and Comoglio PM. Biological activation of pro-HGF (Hepatocyte Growth Factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270: 603-611, 1995.
21. Neuenschwander S and Pliska V. Effects of neurohypophyseal hormone analogues on blood clotting factor VIII and fibrinolytic activity in sheep. Eur J Pharmacol 323: 205-213, 1997.
22. Nilson L, Reinheimer T, Steinwall M, and Åkerlund M. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. Br J Obstet Gynaecol 110: 1025-1028, 2003.
23. North WG, Fay MJ, and Du Jinlin. MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20: 837-842, 1999.
24. Patchev VK, Kalogeras KT, Zelazowski P, Wilder RL, and Chrousos GP. Increased plasma vasopressin concentrations, hypothalamic content and release in inflammatory disease-prone, hypothalamic CRH-deficient. Lewis rat. Endocrinology 131: 1453-1457, 1992.
25. Patchev VK, Mastorakos G, Brady LS, Redwine J, Wilder RL, and Chrousos GP. Increased arginine vasopressin secretion may participate in the enhanced susceptibility of Lewis rats to inflammatory disease. Neuroendoendocrinology 58: 106-110, 1993.
26. Richardson DW and Robinson AG. Desmopressin. Ann Intern Med 103: 228-239, 1985.
27. Sato YR, Tubori R, Lyons R, Moses H, and Rifkin DB. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 111: 757-763, 1990.
28. Schwartz J, Liard JF, Ott C, and Cowley Jr AW. Hemodynamic effects of neurohypophysial peptides with antidiuretic activity in dogs. Am J Physiol Heart Circ Physiol 249: H1001-H1008, 1985.
29. Sekiya S, Oosaki T, Suzuki N, and Takamizawa H. Invasion potential of human choriocarcinoma cell lines and the role of lytic enzymes. Gynecol Oncol 22: 324-333, 1985.
30. Son MC and Brinton RD. Vasopressin-induced calcium signaling in cultured cortical neurons. Brain Res 793: 244-254, 1998.
31. Sugita K, Suzuki N, Isogai E, and Niimi H. Insusceptibility of Cockayne syndrome-derived lymphocytes to plasminogen activator-like protease protease induction by ultraviolet rays and its abolition by interferon. Mutat Res 262: 139-144, 1991.
32. Sugita K, Suzuki N, Isogai E, and Niimi H. Serum factors responsible for unusual induction of plasminogen activator activity in tuberous sclerosis. J Neurol Sci 108: 202-206, 1992.
33. Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, and Niimi N. Involvement of cytokines in N-methyl-N′-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol 33: 358-362, 1993.
34. Takahashi S, Chi XJ, Nomura J, Sugaya S, Kita K, and Suzuki N. A novel method of analyzing environmental chemical mutagens in human cell systems. Water Sci and Technol 42: 133-138, 2000.
35. Tepperman J. Metabolic and Endocrine Physiology. Chicago, IL: Year Book Medical Publishers, 1980, vol. 78.
36. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, and Mattera R. Molecular pharmacology of human vasopressin receptors. In: Vasopressin and Oxytocin, edited by Zingg HH, Bourque CW, and Bichet DG. New York: Plenum, 1998.
37. Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, and Erzurum SC. Human vascular endotherial cells express oxytocin receptors. Endocrinology 140: 1301-1309, 1999.
38. Wickramasinghe SN, Valdimarsson H, and Williams B. Interaction between a synthetic analogue of vasopressin and human peripheral lymphocytes. J Clin Lab Immunol 7: 67-70, 1982.
39. Yamada K, Hatakeyama E, Sakamaki T, Nishimura M, Arita S, Sakamoto K, Hamaguchi K, Nakajima K, Otuka M, and Tanabe K. Involvement of platelet-derived growth factor and histocompatibility of DRB 1 in chronic renal allograft nephropathy. Transplantation 71: 936-941, 2001.
40. Yamada K, Nakayama M, Nakano H, Mimura N, and Yoshida S. Endothelium-dependent vasorelaxation evoked by desmopressin and involvement of nitric oxide in rat aorta. Am J Physiol Endocrinol Metab 264: E203-E207, 1993.